Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy
Nelson Jumbe, … , Michael H. Miller, George L. Drusano
Nelson Jumbe, … , Michael H. Miller, George L. Drusano
Published July 15, 2003
Citation Information: J Clin Invest. 2003;112(2):275-285. https://doi.org/10.1172/JCI16814.
View: Text | PDF
Article Infectious disease

Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy

  • Text
  • PDF
Abstract

The worldwide increase in the prevalence of multi-antibiotic–resistant bacteria has threatened the physician’s ability to provide appropriate therapy for infections. The relationship between antimicrobial drug concentration and infecting pathogen population reduction is of primary interest. Using data derived from mice infected with the bacterium Pseudomonas aeruginosa and treated with a fluoroquinolone antibiotic, a mathematical model was developed that described relationships between antimicrobial drug exposures and changes in drug-susceptible and -resistant bacterial subpopulations at an infection site. Dosing regimens and consequent drug exposures that amplify or suppress the emergence of resistant bacterial subpopulations were identified and prospectively validated. Resistant clones selected in vivo by suboptimal regimens were characterized. No mutations were identified in the quinolone resistance–determining regions of gyrA/B or parC/E. However, all resistant clones demonstrated efflux pump overexpression. At base line, MexAB-OprM, MexCD-OprJ, and MexEF-OprN were represented in the drug-resistant population. After 28 hours of therapy, MexCD-OprJ became the predominant pump expressed in the resistant clones. The likelihood of achieving resistance-suppression exposure in humans with a clinically prescribed antibiotic dose was determined. The methods developed in this study provide insight regarding how mathematical models can be used to identify rational dosing regimens that suppress the amplification of the resistant mutant population.

Authors

Nelson Jumbe, Arnold Louie, Robert Leary, Weiguo Liu, Mark R. Deziel, Vincent H. Tam, Reetu Bachhawat, Christopher Freeman, James B. Kahn, Karen Bush, Michael N. Dudley, Michael H. Miller, George L. Drusano

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
P. aeruginosa dose response. Normal mice were inoculated with about 107 ...
P. aeruginosa dose response. Normal mice were inoculated with about 107 (a) or 108 (b) bacteria per thigh. The levofloxacin MIC and MBC were 0.8 μg/ml and 1.6 μg/ml, respectively. The x axis displays the exposures in mg/kg doses. The model allowed calculation of the dose necessary to achieve stasis (i.e., to return the colony counts at sacrifice to that used for the challenge), as well as 1, 2, and 3 log10 (CFUs/g) reductions in bacterial counts from the stasis point. These data are displayed in the inset as AUC/MIC ratio values for each of these degrees of drug effect. Comparison of microbiological outcome endpoints shows that levofloxacin treatment of P. aeruginosa infections is inoculum dependent. Isolation of drug-resistant P. aeruginosa mutants in vitro was common and occurred with a frequency of 0.1 × 10–6 to 2 × 10–6. At the higher infection inoculum, the microbial population burden significantly exceeded the mutation frequency. At exposures that killed the sensitive population, the resistant population was able to survive. This allowed this subpopulation to be selected and amplified by the drug pressure. Subsequently, a subpopulation of mutant organisms that behaved quite differently under antibiotic pressure emerged. Only with sufficient exposure to inhibit and kill the resistant subpopulation do we attain larger overall reduction of bacterial load.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts